Navigation Links
USPTO Grants Butamax a Further KARI Enzyme Patent
Date:7/17/2012

WILMINGTON, Del., July 17, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, today announced the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,222,017 which protects a subset of key enzymes in the isobutanol production pathway.  

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"We are pleased with the progress of our patent applications at the USPTO and this particular patent shows the expansion of our portfolio not just covering the fundamental pathway, but also protecting key pathway enzymes, far in advance of others in the field," commented Paul Beckwith, Butamax CEO, "This patent, and others like it soon to grant, demonstrates Butamax's strong innovation capability."

This latest patent issued from a series of applications covering a full-range of modified KARI enzymes. In this case, the enzyme subset is based on KARI enzymes having a modification that provides production efficiencies through the fundamental isobutanol biosynthetic pathway invented by Butamax. 

Butamax inventions include recombinant microorganisms that convert various feedstocks to biobutanol, process engineering for recovering biobutanol produced during fermentation, engineering design for optimized energy integrations, and various renewable fuel and chemical compositions. The depth and breadth of the portfolio reflects the synergy between Butamax's investors, BP and DuPont, as world class scientists and leaders in the biofuels industry. 

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact: Pam Schools  
910-777-7119  
pamela.schools@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
2. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
3. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
4. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
8. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
9. Butamax™ Responds to Gevo Patent Infringement Lawsuit
10. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
11. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):